Althera Laboratories licenses a type 2 diabetes combination therapy to Tabuk for MENA

MENA-region scope only; no African country is named in the release or the syndicated copy reviewed.


Coverage: The Meridian legal market record (editorial).

MENA-region scope only; no African country is named in the release or the syndicated copy reviewed.

Record ID TX-AFR-2025-0015
Record type Commercial IP transaction
Transaction type Patent licence, In-licensing, Trade mark licence
IP rights patent, regulatory data, trade mark
Status Signed
Qualifying date 2025-12-03
Sector Life sciences · Pharmaceuticals – cardiometabolic
African markets Multi-jurisdictional
Licensed territory MENA region.
Disclosed value Not disclosed in the sources reviewed.
Evidence Primary source, single · 1 source(s)
Last verified 2026-10-25

Parties

  • Althera Laboratories Limited (Ireland): licensor
  • Tabuk Pharmaceuticals (Saudi Arabia): licensee

Key terms

  • Interest: licence; Exclusivity: not stated by source; Territorial scope: MENA region

Sources

  1. Althera Laboratories and Tabuk Pharmaceuticals Announce Strategic Partnership for Advanced T2D Therapy in MENA, Althera Laboratories / Tabuk Pharmaceuticals (via EIN Presswire, carried by National Law Review), 2025-12-03

Part of The Meridian’s Africa IP database. Counts, market breakdowns and rankings are derived from published records only; a record counts once. Corrections: submit evidence.